What is spiradenocarcinoma?
Spiradenocarcinoma is a rare skin cancer that develops from structures linked to the sweat glands. In most cases it arises within a spiradenoma, a benign sweat gland tumour that may have been present for many years. It is also known as malignant spiradenoma or malignant eccrine spiradenoma.
Spiradenocarcinoma is one of the adnexal carcinomas, a family of cancers that start in the skin’s “appendages”, such as sweat glands and hair follicles. It is extremely uncommon. A study of the large US cancer registry found only 90 cases over twenty years (Martineau et al., 2023).
The typical story is a small lump that has been present for years and then starts to grow quickly, change colour, become painful or bleed (Staiger et al., 2017). The disease mainly affects people around 60, and men and women are affected in similar numbers.
Its behaviour varies. Low-grade tumours, which are more common, usually stay local and are cured by surgery. High-grade tumours are more aggressive and can spread to lymph nodes, lungs, bones and liver. The main treatment is wide surgical removal, with lymph node surgery when needed.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Malignant adnexal (sweat gland-related) skin tumour |
| Also called | Malignant spiradenoma; malignant eccrine spiradenoma |
| How common | Extremely rare |
| Typical age | Around 60; usually adults |
| Sex | Men and women equally |
| Typical history | A long-standing lump that suddenly grows |
| Main sites | Head, neck, trunk and limbs; anywhere with sweat glands |
| Main treatment | Wide local excision; lymph node surgery if involved |
| Outlook | Good for low-grade tumours; poorer for high-grade tumours |
2. Types of spiradenocarcinoma
By grade
| Grade | Features | Behaviour |
|---|---|---|
| Low grade | Cells only mildly abnormal; some residual benign pattern | Mostly local; good outlook |
| High grade | Very abnormal cells, many mitoses, necrosis | More likely to recur, spread and cause death |
Low-grade tumours have been reported more than three times as often as high-grade ones, but the high-grade tumours carry most of the risk (Staiger et al., 2017).
Related tumours
| Tumour | Description |
|---|---|
| Spiradenoma | Benign; a well-defined, often painful nodule |
| Atypical spiradenoma | Shows some worrying features but not definite cancer |
| Cylindroma | Benign related tumour, often on the scalp |
| Cylindrocarcinoma | Malignant counterpart of cylindroma |
| Spiradenocylindrocarcinoma | Contains features of both |
How it compares with other skin cancers
| Feature | Spiradenocarcinoma | Basal cell carcinoma | Squamous cell carcinoma |
|---|---|---|---|
| Frequency | Extremely rare | Very common | Common |
| Usual history | Old lump that changes | Slowly growing pearly lump | Scaly, growing lump or sore |
| Link with sun | Weak | Strong | Strong |
| Spread | Possible, especially high grade | Very rare | Uncommon |
| Main treatment | Wide excision | Excision, Mohs and other options | Excision |
3. Causes and risk factors
The cause is not fully understood. Most spiradenocarcinomas appear to develop from a benign spiradenoma that has undergone malignant change (Wagner et al., 2021).
| Factor | Notes |
|---|---|
| Long-standing spiradenoma | The main risk factor; often present for many years |
| Older age | Most cases occur after 50 |
| CYLD cutaneous syndrome (Brooke-Spiegler syndrome) | Inherited condition with many cylindromas, spiradenomas and trichoepitheliomas; higher risk of malignant change |
| Fair skin | More common in white people in published series |
People with CYLD cutaneous syndrome often have multiple skin lumps and need regular skin checks for any that change.
Skin appendages and their cancers
| Skin structure | Normal role | Examples of cancers |
|---|---|---|
| Eccrine sweat glands | Produce watery sweat for cooling, all over the body | Porocarcinoma, hidradenocarcinoma |
| Apocrine glands | Found mainly in the armpits and groin | Apocrine carcinoma, extramammary Paget disease |
| Hair follicles | Produce hair | Pilomatrix carcinoma, trichilemmal carcinoma |
| Sebaceous glands | Produce oily sebum | Sebaceous carcinoma |
| Uncertain (spiradenoma family) | Related to sweat gland structures | Spiradenocarcinoma, cylindrocarcinoma |
All of these cancers are rare, and they are often diagnosed only after a lump has been removed and examined.
CYLD cutaneous syndrome
This inherited condition is caused by a change in the CYLD gene. People with it develop many benign skin tumours, often on the scalp and face, beginning in early adulthood. The tumours include cylindromas, spiradenomas and trichoepitheliomas.
Each one has a small risk of becoming malignant, so regular skin reviews and prompt removal of any lump that changes are recommended. Relatives may be offered genetic testing.
4. How does it look
On the skin
| Feature | Description |
|---|---|
| Shape | A firm nodule or lump, sometimes with several lumps together |
| Colour | Skin-coloured, pink, red, bluish or purple |
| Surface | Smooth at first; may ulcerate or bleed |
| Size | Often 1-5 cm; can become larger |
| Change | A sudden increase in size of an old lump |
| Tenderness | Spiradenomas are often painful, and so may the carcinoma be |
On scans
Ultrasound or MRI shows how deep the tumour extends. PET-CT and CT are used to look for spread, especially for high-grade tumours (Staiger et al., 2017).
Under the microscope
| Feature | Description |
|---|---|
| Background | Often a residual benign spiradenoma |
| Transition | An abrupt change from benign to malignant areas |
| Cell pattern | Loss of the normal two-cell population, replaced by uniform abnormal cells |
| Mitoses | Atypical dividing cells |
| Necrosis | Present in some tumours |
| Stains | Higher Ki-67 and p53 in malignant areas |
These features help pathologists distinguish spiradenocarcinoma from an atypical but benign spiradenoma (Huang et al., 2019).
5. Symptoms
Common symptoms
- A lump that has been present for years and starts to grow quickly
- A change in colour or appearance of an old lump
- Pain or tenderness
- Bleeding or ulceration
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Lumps in nearby lymph nodes | Regional spread |
| Cough or breathlessness | Lung spread |
| Bone pain | Bone spread |
| Tiredness and weight loss | Advanced disease |
When to seek medical advice
See a doctor about any skin lump that changes, especially one that has been present for a long time and then grows, bleeds or becomes painful. Prompt removal and examination under the microscope is the only way to be sure.
6. Diagnosis
| Test | Purpose |
|---|---|
| Skin examination and dermoscopy | Assesses the lump and surrounding skin |
| Biopsy or excision | Confirms the diagnosis and grade |
| Lymph node examination and ultrasound | Checks nearby nodes |
| MRI | Defines the depth and extent of the tumour |
| PET-CT or CT | Looks for spread, especially with high-grade tumours |
| Fine needle aspiration of nodes | If nodes are enlarged |
Because the tumour is rare and can resemble other skin cancers, the slides are often reviewed by a specialist dermatopathologist.
Why a pathologist’s review matters
Benign spiradenomas can contain areas that look unusual under the microscope. Telling an atypical spiradenoma from a true spiradenocarcinoma, and then grading the cancer, requires careful assessment of the whole specimen. The pathologist looks for an abrupt switch from benign to malignant tissue, loss of the two normal cell types, abnormal dividing cells and dead tissue. Special stains such as Ki-67 and p53 can highlight the malignant areas (Huang et al., 2019).
The final grade guides how much further treatment and imaging are needed.
Staging
There is no staging system specific to spiradenocarcinoma. Doctors usually describe:
| Element | Meaning |
|---|---|
| Local disease | Confined to the skin and tissue beneath |
| Regional disease | Spread to nearby lymph nodes |
| Distant disease | Spread to lungs, bones, liver or other organs |
In the US registry, regional or distant spread at diagnosis was uncommon, together accounting for only about 5% of cases (Martineau et al., 2023).
7. Treatment
Surgery
| Procedure | Notes |
|---|---|
| Wide local excision | The main treatment; margins of about 1 cm or more are often recommended |
| Mohs micrographic surgery | Used in some centres, especially on the face |
| Sentinel lymph node biopsy | Considered in selected high-risk cases |
| Lymph node dissection | If nodes contain cancer |
| Reconstruction | Skin graft or flap for larger wounds |
A literature review recommended wide local excision aiming for margins of at least 1 cm, with node surgery decided case by case (Wagner et al., 2021). Most patients in the US registry were treated with surgery alone (Martineau et al., 2023).
Radiotherapy
| Situation | Role |
|---|---|
| Close or positive margins | May reduce local recurrence |
| Lymph node spread | After node surgery |
| Unresectable or painful disease | For symptom control |
Drug treatment
For spread to distant organs there is no standard drug treatment. Chemotherapy has been used with limited success. Immunotherapy (PD-1 inhibitors) has produced responses in individual reported cases, and clinical trials may be considered.
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Scarring, wound infection, numbness |
| Lymph node surgery | Swelling (lymphoedema), stiffness |
| Radiotherapy | Skin redness, tiredness, hair loss in the treated area |
| Immunotherapy | Rash, diarrhoea, inflammation of organs |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Excision | Usually a day case under local or general anaesthetic |
| Wound care | Dressings for 1-2 weeks; stitches removed at 1-2 weeks |
| Node surgery | A short hospital stay and a drain |
| Radiotherapy | Weekday sessions for several weeks if needed |
8. Outlook (prognosis)
Estimates of outlook vary widely between data sources.
| Source | Findings |
|---|---|
| US registry (90 cases) | Five-year disease-specific survival about 96%; overall survival about 76% (Martineau et al., 2023) |
| Literature review (182 cases) | Local recurrence about 21%, metastasis about 37%, death about 19% (Wagner et al., 2021) |
The difference probably reflects the fact that published case reports tend to describe unusual, aggressive cases. The registry data suggest that the risk of dying from the disease is lower than once thought (Martineau et al., 2023).
| Factor | Effect |
|---|---|
| Low grade | Better outlook |
| High grade | Higher risk of recurrence and death |
| Clear margins | Lower risk of recurrence |
| Cancer-free lymph nodes | Better outlook |
| Distant spread | Poor outlook |
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic review every 3-6 months at first | Checks the scar and lymph nodes |
| Imaging | CT or PET-CT, particularly for high-grade tumours |
| Skin checks | Especially in CYLD cutaneous syndrome |
| Longer-term reviews | Once or twice a year after the first few years |
Experts recommend frequent follow-up with imaging in the early years, particularly for high-grade tumours (Staiger et al., 2017).
10. Living with spiradenocarcinoma
- Check your scar and nearby lymph nodes each month
- Report new lumps, cough or bone pain promptly
- Protect your skin from the sun, as for any skin cancer
- Look after your wound and keep it clean while it heals
- Ask about genetic advice if you have many similar skin lumps or a family history
- Keep a photo record of any other skin lumps so changes are easier to spot
- Seek support from skin cancer and rare cancer charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| Did my old lump turn into cancer? | Most spiradenocarcinomas arise in an old benign spiradenoma |
| Is it a sweat gland cancer? | Yes, it is related to sweat gland structures |
| Can it spread? | Yes, especially high-grade tumours |
| Will I need chemotherapy? | Usually not; surgery is the main treatment |
| Is it inherited? | Usually not, except with CYLD cutaneous syndrome |
| Can it come back after surgery? | Yes, particularly if margins were close, which is why regular checks matter |
| Is it caused by the sun? | No strong link has been shown |
| Why do sources give different survival figures? | Case reports tend to describe severe cases, while registries include milder ones |
| Will I have a large scar? | It depends on the size and site; reconstruction can help |
| How long will follow-up last? | Usually at least 5 years, with more frequent visits at first |
12. Questions to ask your care team
- Is my tumour low grade or high grade?
- Were the margins clear, and how wide were they?
- Do I need lymph node tests or surgery?
- Should I have a PET-CT or other scans?
- Do I need radiotherapy?
- How often should I come for follow-up?
- Has my biopsy been reviewed by a specialist skin pathologist?
- Should my family be offered any tests?
Resources
- Huang, A. et al. (2019) ‘Histological findings and pathologic diagnosis of spiradenocarcinoma: a case series and review of the literature’, Journal of Cutaneous Pathology, 46(4), pp. 243-250.
- Martineau, J. et al. (2023) ‘Spiradenocarcinoma: SEER study of epidemiology, survival, and treatment options’, Journal of Clinical Medicine, 12(5), 2045.
- Staiger, R.D. et al. (2017) ‘Spiradenocarcinoma: a comprehensive data review’, American Journal of Dermatopathology, 39(10), pp. 715-725.
- Wagner, K. et al. (2021) ‘Challenges in diagnosis and management of a spiradenocarcinoma: a comprehensive literature review’, ANZ Journal of Surgery, 91(10), pp. 1996-2001.
Prepared by the editorial team, October 2026.